September 11, 2024
MADRID — An artificial intelligence (AI)-driven voice algorithm showed “excellent agreement” with the American Diabetes Association (ADA) risk test in detecting adults with type 2 diabetes […]
September 10, 2024
MADRID, Spain — The nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone reduced the incidence of new-onset type 2 diabetes by approximately 25% in patients with heart failure […]
September 10, 2024
MADRID, Spain — Nearly half of people with type 2 diabetes (T2D) currently recommended to receive sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney protection would not […]
September 10, 2024
MADRID — Night owls — individuals with late chronotypes — may be at an increased risk for type 2 diabetes (T2D), beyond the risks conferred by […]
September 9, 2024
TOPLINE: MADRID — Impaired circadian heart rate (HR) fluctuations are linked to increased cardiovascular and all-cause mortality in patients with long-standing diabetes. METHODOLOGY: Researchers analyzed data […]
September 9, 2024
TOPLINE: Adopting low-carbohydrate or low-fat diets over the short term doesn’t change gut-derived appetite hormones at the same levels as observed with pharmacologic treatments or bariatric […]
September 9, 2024
(Reuters) -Rezolute Inc said on Monday the U.S. Food and Drug Administration had lifted its partial clinical hold on a late-stage study testing the company’s treatment […]
September 9, 2024
(Reuters) -Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early-stage study, joining drugmakers vying for a share of […]
September 9, 2024
Tirzepatide (Zepbound) is not in shortage for now, but the weight loss drug has remained inaccessible to people without insurance coverage who can’t afford to pay […]